Brief: Synact Pharma Q2 Group Loss After Tax At SEK 22 Mln
20/08/2026 06:37
BRIEF-Synact Pharma Q2 Group Loss After Tax At SEK 22 Mln Aug 20 (Reuters) - SynAct Pharma AB SYNACT.ST:
Q2 NET SALES AMOUNT TO 0 TSEK
Q2 OPERATING EXPENSES DECREASE 19% TO 24,556 TSEK
Q2 GROUP LOSS AFTER TAX AMOUNTS TO 22,032 TSEK
Source text: ID:nMFN3w62vX
Further company coverage: SYNACT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development